Skip to main content

Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

Written by Customer Service on . Posted in Public Companies.

REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company and its collaborators will present preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023 being held April 14-19, 2023, in Orlando, Florida.

Details of the planned presentations are listed below:

Revolution Medicines Oral Presentations:

Title: Discovery of RMC-6291, a tri-complex KRASG12C(ON) inhibitor
Presenter:  Jim Cregg, Ph.D.
Abstract Number: ND07
Session:  New Drugs on the Horizon: Part 2
Date/Time:  3:45 – 4:00 p.m. Eastern on April 16, 2023

Title:  RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models
Presenter: Marie Menard, Ph.D.
Abstract Number:  3475
Session: Immune Checkpoints at Tumor Beds
Date/Time:  3:37 – 3:52 p.m. Eastern on April 17, 2023

Revolution Medicines Poster Presentations:

Title: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers
Presenter: Lingyan Jiang, Ph.D.
Abstract Number: 526/26
Session: Novel Antitumor Agents 2
Date/Time: 1:30 – 5:00 p.m. Eastern on April 16, 2023

Title: RMC-0708 (RM-046), a first-in-class, mutant-selective and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target
Presenter:  Yu C. Yang, Ph.D.
Abstract Number: 1598/21
Session: New Therapeutic Targeted Agents
Date/Time: 9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023

Collaborator Oral Presentation:

Title:  Combining KRASG12C(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer
Abstract Number: 5733
Session:  New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling
Presentation Time:  2:37 – 2:52 p.m. Eastern on April 18, 2023

Collaborator Poster Presentations:

Title: Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression
Abstract Number: LB015/7
Session: Late-Breaking Research: Experimental and Molecular Therapeutics 1
Presentation Time: 1:30 – 5:00 p.m. Eastern on April 16, 2023

Title: Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma
Abstract Number:  1725/22
Session:  Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2
Date/Time: 9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023

Title: Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1
Abstract Number: 4859/2
Session: Anticancer Approaches Targeting Signal Transduction Pathways
Presentation Time: 1:30 – 5:00 p.m. Eastern on April 18, 2023

Additional information on the AACR Annual Meeting 2023 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2023/

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI) and RMC-6291(KRASG12C) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRASG12D) and RMC-0708 (KRASQ61H), both of which are currently in IND-enabling development, RMC-8839 (KRASG13C), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

 

CONTACT: Contacts:

For Investors & Media:
Erin Graves
650-779-0136
egraves@revmed.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.